[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CO5210862A1 - Formas de dosificacion y metodos para proporcionar efectiva terapia de reboxetina con dosificacion de una vez al dia - Google Patents

Formas de dosificacion y metodos para proporcionar efectiva terapia de reboxetina con dosificacion de una vez al dia

Info

Publication number
CO5210862A1
CO5210862A1 CO00069700A CO00069700A CO5210862A1 CO 5210862 A1 CO5210862 A1 CO 5210862A1 CO 00069700 A CO00069700 A CO 00069700A CO 00069700 A CO00069700 A CO 00069700A CO 5210862 A1 CO5210862 A1 CO 5210862A1
Authority
CO
Colombia
Prior art keywords
reboxetine
dosage
day
methods
effective therapy
Prior art date
Application number
CO00069700A
Other languages
English (en)
Inventor
Sylvia Seroff
Yam Noymi
D Ayer Atul
Bhatt Padmanabh
Michael A Desjardin
Phillip R Nixon
Edgren David Emil
Andrew C Lam
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Publication of CO5210862A1 publication Critical patent/CO5210862A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Una forma de dosificación de liberación sostenida adaptada para la liberación de reboxetina a un índice uniforme, durante un período de tiempo prolongado.La forma de dosificación de la reivindicación 1, en donde la forma de dosificación de liberación sostenida es una composición osmótica que comprende un componente que contiene reboxetina en mezcla con un agente osmótico dentro de un compartimiento interno; dicho compartimiento interno es definido por una membrana semipermeable a través de la cual se suministra reboxetina por medio de un orificio de suministro formado, o capaz de ser formado, en dicha membrana semipermeable.<EMI FILE="00069700_1" ID="1" IMF=JPEG >
CO00069700A 1999-09-15 2000-09-14 Formas de dosificacion y metodos para proporcionar efectiva terapia de reboxetina con dosificacion de una vez al dia CO5210862A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15399799P 1999-09-15 1999-09-15

Publications (1)

Publication Number Publication Date
CO5210862A1 true CO5210862A1 (es) 2002-10-30

Family

ID=22549601

Family Applications (1)

Application Number Title Priority Date Filing Date
CO00069700A CO5210862A1 (es) 1999-09-15 2000-09-14 Formas de dosificacion y metodos para proporcionar efectiva terapia de reboxetina con dosificacion de una vez al dia

Country Status (13)

Country Link
US (2) US6387403B1 (es)
EP (1) EP1216031B1 (es)
JP (1) JP2003509354A (es)
KR (2) KR100723850B1 (es)
AR (1) AR031978A1 (es)
AT (1) ATE356619T1 (es)
AU (1) AU7490700A (es)
CA (1) CA2384624C (es)
CO (1) CO5210862A1 (es)
DE (1) DE60033947T2 (es)
PE (1) PE20010625A1 (es)
TW (1) TWI233809B (es)
WO (1) WO2001019337A2 (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0203296D0 (en) * 2002-02-12 2002-03-27 Glaxo Group Ltd Novel composition
WO2003092649A2 (en) * 2002-04-29 2003-11-13 Alza Corporation Reduced formate poly(alkylene oxides) with secondary amines for reducing impurity formation
US20070196481A1 (en) * 2002-07-25 2007-08-23 Amidon Gregory E Sustained-release tablet composition
US20050226926A1 (en) 2002-07-25 2005-10-13 Pfizer Inc Sustained-release tablet composition of pramipexole
US20050232995A1 (en) 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
US8637512B2 (en) * 2002-07-29 2014-01-28 Glaxo Group Limited Formulations and method of treatment
US20070077301A1 (en) * 2002-12-23 2007-04-05 Meyer Glenn A Venlafaxine osmotic device formulation
US8293799B2 (en) * 2003-12-29 2012-10-23 Osmotica Keresleedelmo és Szolgáltató KFT Osmotic device containing a venlafaxine salt and a salt having an ion in common
DE602004015246D1 (de) * 2003-02-11 2008-09-04 Alza Corp Verfahren und dosierformen mit modifizierter schichtgeometrie
EP1603540A2 (en) * 2003-03-14 2005-12-14 Nirmal Mulye A process for preparing sustained release tablets
DK2316456T3 (en) 2003-04-29 2017-09-11 Orexigen Therapeutics Inc Compositions for affecting weight loss comprising an opioid antagonist and bupropion
DK1575565T3 (da) * 2003-08-08 2010-04-12 Biovail Lab Int Srl Tablet med modificeret frigivelse af bupropion-hydrochlorid
US20050131028A1 (en) * 2003-09-11 2005-06-16 Pharmacia Corporation Methods and compositions for the extended duration treatment of pain, inflammation and inflammation-related disorders
US20070259033A1 (en) * 2003-09-26 2007-11-08 Evangeline Cruz Controlled release formulations exhibiting an ascending rate of release
NZ546148A (en) 2003-09-26 2009-05-31 Alza Corp Drug coating providing high drug loading and methods for providing the same
US20050182122A1 (en) * 2003-11-20 2005-08-18 Bello Carlo L. Method of treating abnormal cell growth using indolinone compounds
US20050265955A1 (en) * 2004-05-28 2005-12-01 Mallinckrodt Inc. Sustained release preparations
EA015335B1 (ru) 2004-08-13 2011-06-30 Бёрингер Ингельхайм Интернациональ Гмбх Композиция таблетки пролонгированного высвобождения, содержащая прамипексол или его фармацевтически приемлемую соль, способ ее изготовления и ее применение
AR053986A1 (es) 2004-12-03 2007-05-30 Osmotica Pharmaceutical Argent Dispositivo osmotico que contiene amantadina y una sal osmotica
CA2611430C (en) * 2005-06-09 2013-09-10 Euro-Celtique S.A. Pharmaceutical compositions of a neuroactive steroid and uses thereof
US20070190137A1 (en) * 2005-10-07 2007-08-16 Reyes Iran Osmotic dosage form with controlled release and fast release aspects
MX337422B (es) 2005-11-22 2016-03-04 Orexigen Therapeutics Inc Composiciones y metodos para incrementar la sencibilidad a la insulina.
WO2007089318A2 (en) * 2005-11-23 2007-08-09 Orexigen Therapeutics, Inc. Compositions and methods for reducing food cravings
US20070128282A1 (en) * 2005-12-02 2007-06-07 Patel Hasmukh B Oral osmotic drug delivery system
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
US20080110792A1 (en) 2006-11-09 2008-05-15 Orexigen Therapeutics, Inc. Methods for administering weight loss medications
MX2009004874A (es) 2006-11-09 2009-06-16 Orexigen Therapeutics Inc Formulaciones farmaceuticas estratificadas que comprenden una capa intermediaria que se disuelve rapidamente.
US7714201B2 (en) * 2006-12-22 2010-05-11 Monsanto Technology Llc Cotton variety 781000G
US7419684B2 (en) * 2006-12-22 2008-09-02 Reliant Pharmaceuticals, Inc. System and method for manufacturing oral osmotic drug delivery devices, and methods of administering same
WO2009158114A1 (en) 2008-05-30 2009-12-30 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
US20100069389A1 (en) * 2008-09-06 2010-03-18 Bionevia Pharmaceuticals, Inc. Novel forms of reboxetine
WO2011078993A1 (en) * 2009-12-21 2011-06-30 Aptapharma, Inc. Functionally-coated multilayer tablets
CA2785822C (en) 2010-01-11 2019-06-25 Orexigen Therapeutics, Inc. Methods of providing weight loss therapy in patients with major depression
KR102059698B1 (ko) * 2011-06-06 2019-12-26 오크 크레스트 인스티튜트 오브 사이언스 심지 방출창을 도입한 약물 전달 장치
US9633575B2 (en) 2012-06-06 2017-04-25 Orexigen Therapeutics, Inc. Methods of treating overweight and obesity
US10716761B2 (en) 2017-07-24 2020-07-21 Alcresta Therapeutics, Inc. Ingestible medical delivery devices
CN111077238A (zh) * 2019-11-12 2020-04-28 北京和合医学诊断技术股份有限公司 检测血液中瑞波西汀药物含量液相色谱分析方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3995631A (en) 1971-01-13 1976-12-07 Alza Corporation Osmotic dispenser with means for dispensing active agent responsive to osmotic gradient
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4077407A (en) 1975-11-24 1978-03-07 Alza Corporation Osmotic devices having composite walls
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4111201A (en) 1976-11-22 1978-09-05 Alza Corporation Osmotic system for delivering selected beneficial agents having varying degrees of solubility
IL56369A (en) 1978-01-20 1984-05-31 Erba Farmitalia Alpha-phenoxybenzyl propanolamine derivatives,their preparation and pharmaceutical compositions comprising them
US4384005A (en) * 1980-09-26 1983-05-17 General Foods Corporation Non-friable, readily-soluble, compressed tablets and process for preparing same
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4519801A (en) 1982-07-12 1985-05-28 Alza Corporation Osmotic device with wall comprising cellulose ether and permeability enhancer
US4578075A (en) 1982-12-20 1986-03-25 Alza Corporation Delivery system housing a plurality of delivery devices
US4681583A (en) 1982-12-20 1987-07-21 Alza Corporation System for dispersing drug in biological environment
GB2167407B (en) 1984-11-22 1988-05-11 Erba Farmitalia Enantiomers of phenoxy derivatives of benzyl morpholine and salts thereof
US5019397A (en) 1988-04-21 1991-05-28 Alza Corporation Aqueous emulsion for pharmaceutical dosage form
US5156850A (en) 1990-08-31 1992-10-20 Alza Corporation Dosage form for time-varying patterns of drug delivery
ES2149781T3 (es) * 1991-11-22 2000-11-16 Procter & Gamble Pharma Composiciones de risedronato de liberacion retardada.
US5688518A (en) * 1992-02-27 1997-11-18 Alza Corporation Antidepressive therapy
WO1995034582A1 (en) 1994-06-16 1995-12-21 Pharmacia S.P.A. Bioadhesive starches and process for their preparation
UA56257C2 (uk) 1997-09-23 2003-05-15 Елі Ліллі Енд Компані Спосіб лікування неадекватної визивної поведінки
UA57107C2 (uk) * 1997-09-23 2003-06-16 Елі Ліллі Енд Компані Спосіб лікування розладу поведінки
JP2001517628A (ja) 1997-09-23 2001-10-09 イーライ・リリー・アンド・カンパニー 注意欠陥／多動障害の治療法
EP0919234A3 (en) 1997-10-17 1999-08-25 Eli Lilly And Company Potentiation of pharmaceuticals by moxonidine

Also Published As

Publication number Publication date
EP1216031A2 (en) 2002-06-26
EP1216031B1 (en) 2007-03-14
JP2003509354A (ja) 2003-03-11
KR20020031424A (ko) 2002-05-01
PE20010625A1 (es) 2001-06-04
TWI233809B (en) 2005-06-11
US6630165B2 (en) 2003-10-07
ATE356619T1 (de) 2007-04-15
DE60033947D1 (de) 2007-04-26
CA2384624A1 (en) 2001-03-22
AU7490700A (en) 2001-04-17
KR100723850B1 (ko) 2007-05-31
DE60033947T2 (de) 2007-11-29
KR20070007215A (ko) 2007-01-12
US20020146453A1 (en) 2002-10-10
KR100831181B1 (ko) 2008-05-21
CA2384624C (en) 2009-12-29
WO2001019337A3 (en) 2001-08-09
WO2001019337A2 (en) 2001-03-22
US6387403B1 (en) 2002-05-14
AR031978A1 (es) 2003-10-22

Similar Documents

Publication Publication Date Title
CO5210862A1 (es) Formas de dosificacion y metodos para proporcionar efectiva terapia de reboxetina con dosificacion de una vez al dia
BRPI0407373A (pt) Espuma hidro-alcoólica formando espuma em filme
MX9207402A (es) Dispositivo osmotico para surtir un agente benefico a la cavidad oral.
UY28067A1 (es) Formulaciones de deposito de liberacion controlada
DE60118395D1 (de) Pharmazeutische zusammensetzungen mit verzögerter freisetzung für die parenterale applikation von hydrophilen wirkstoffen
ES2163504T3 (es) Formas de dosificacion de liberacion controlada de azitromicina.
ECSP034455A (es) Forma de dosificacion de farmaco activada por hidrogel
DE50114147D1 (de) Wärmendes hautreinigungsgel
GT200400242A (es) Uso extendido de combinacion que comprende estrogenos y progestina.
BR0013826A (pt) Formas orais de apresentação
PE88699A1 (es) Formas de dosificacion de liberacion sostenida de sertralina
ATE369125T1 (de) Bioadhäsiver schaumstoffilm mit hinhaltender wirkstoffreigabe
ES2164040T1 (es) Uso de agonistas del sitio de union de la glicina o de inhibidores de la absorcion de la glicina para el tratamiento de trastornos neuropsiquiatricos.
ECSP045451A (es) Metodos y formas de dosificacion para la entrega controlada de oxicodona
BR0107549A (pt) Composição de pró-perfume
AR021858A1 (es) Composicion de liberacion modificada de particulas multiples
BR0311897A (pt) Sistema de liberação osmótica com mecanismo de potência de impulso de ordem zero inicial compreendendo um agente osmótico disperso no veìculo fluido
CL2008003941A1 (es) Uso de escitalopram o de una sal farmaceuticamente aceptable del mismo para preparar un medicamento util en el tratamiento del desorden compulsivo obsesivo.
ATE259237T1 (de) Verwendung von isoosmotischen salzlösungen zur verhütung von entzündungen
ATE168886T1 (de) Abgabevorrichtung mit eingekapselten hilfsmitteln
DE60026146D1 (de) Verwendung von dapoxetin, a selektiver serotonin-aufnahme inhibitor mit schnellem wirkungseintritt, zur behandlung von sexueller dysfunction
BR0107667A (pt) Composto de linezolida em forma de cristal que e farmaceuticamente útil como agente antibacteriano e método de preparação do mesmo
FI964253A0 (fi) Kollageenivalmiste vaikuttavien aineiden säädellyksi vapauttamiseksi
AR241747A1 (es) Dispositivo de bolo de liberacion controlada.
DE69935853D1 (de) Anwendung von alfa1beta1 integrinrezeptorinhibitoren und tgf-beta1-inhibitoren zur behandlung von nierenkrankheiten

Legal Events

Date Code Title Description
FC Application refused